http://orcid.org/0000-0002-9421-3087
References
- Aniwan S, Park SH, Loftus EV. Epidemiology, natural history, and risk stratification of Crohn’s disease. Gastroenterol Clin North Am. 2017;46(3):463–480.
- Pariente B, Mary J-Y, Danese S, et al. Development of the Lémann Index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148(1):52–63.e3.
- Amitai MM, Zarchin M, Lahat A, et al. Structural bowel damage in quiescent Crohn’s disease. Dig Liver Dis. 2017;49(5):490–494.
- Fiorino G, Bonifacio C, Allocca M, et al. Bowel damage as assessed by the Lémann Index is reversible on anti-TNF therapy for Crohn’s disease. J Crohns Colitis. 2015;9(8):633–639.
- Panchal H, Wagner M, Chatterji M, et al. Earlier anti-tumor necrosis factor therapy of Crohn’s disease correlates with slower progression of bowel damage. Dig Dis Sci. 2019;64(11):3274–3283.
- Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25.
- Lunder AK, Jahnsen J, Bakstad LT, et al. Bowel damage in patients with long-term Crohn’s disease, assessed by magnetic resonance enterography and the Lémann Index. Clin Gastroenterol Hepatol. 2018;16(1):75–82.e5.
- Bodini G, Giannini EG, De Maria C, et al. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn’s disease. A study performed using the Lémann Index. Dig Liver Dis. 2017;49(2):175–180.
- Tanaka H, Kamata N, Yamada A, et al. Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn’s disease. J Gastroenterol Hepatol. 2018;33(5):1031–1038.
- Actis GC, Pellicano R, Ribaldone DG. A concise history of thiopurines for inflammatory bowel disease: from anecdotal reporting to treat-to-target algorithms. Rev Recent Clin Trials. 2019;14(1):4–9.
- Fiorino G, Caprioli F, Daperno M, et al. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2019;51(5):632–639.